US Inflation Reduction Act Pipeline Considerations

This document is a technical report that outlines a risk exposure framework for drug developers in relation to the US Inflation Reduction Act (IRA). The IRA introduces significant changes to healthcare access and drug pricing, particularly affecting Medicare's ability to negotiate drug prices. The report details a framework developed to analyze pipeline assets for IRA risk exposure, utilizing five criteria to assess asset-level risk, prioritize investments, and forecast overall pipeline risk and revenue potential. The criteria include considerations such as the Medicare patient population, small molecule penalties, disease area competition, value differentiation, and multiple indication strategies. The report also presents hypothetical product profiles, each evaluated for IRA-related risks and weighted risk scores, along with recommendations for risk mitigation and strategic planning. The aim is to help drug developers navigate the complexities of the IRA and optimize their product development strategies in light of these new regulations.